Brief: Hanmi Pharmaceutical: Janssen Pharmaceuticals Decides To Return Rights For Obesity/Diabetes Drug To Hanmi
July 3 (Reuters) - Hanmi Pharm Co Ltd 128940.KS Says:
* JANSSEN PHARMACEUTICALS DECIDES TO RETURN RIGHTS FOR
OBESITY/DIABETES DRUG, HM12525A, TO HANMI
* IT WILL NOT RETURN AN UPFRONT PAYMENT OF $105 MILLION TO
JANSSEN
PHARMACEUTICALS
Source text for Eikon in Korean: https://bit.ly/2LzJ6HY
Further company coverage: 128940.KS
((Heekyong.Yang@thomsonreuters.com;))
Recent news on Hanmi Pharm
See all newsBrief: Hanmi Pharm To Cancel 28 Billion Won Worth Of Own Shares
Brief: Hanmi Pharm Q3 Operating Profit 37.8 Billion Won, Down 31.3% From Year Earlier
Brief: Hanmi Pharm Co Signs License Out Agreement With Genetech Inc. In U.S.
Brief: Hanmi Pharm Co Enters License Agreement With Eli Lilly For Sonefpeglutide
Brief: Hanmi Pharm Co Ltd Wins 53 Billion Won Order